Christopher Rovaldi
Chief Operating Officer at KEROS THERAPEUTICS, INC.
Net worth: - $ as of 2024-05-30
Profile
Christopher Rovaldi is SVP-Program Management & Operations at Acceleron Pharma, Inc. Mr. Rovaldi previously held the position of Director-Project Management at Idenix Pharmaceuticals LLC, Senior Research Associate of Periodontix, Inc. and Director-Project Management at Cubist Pharmaceuticals LLC. He received a graduate degree and an undergraduate degree from the University of New Hampshire.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
KEROS THERAPEUTICS, INC.
-.--% | 2024-03-30 | 0 ( -.--% ) | - $ | 2024-05-30 |
Christopher Rovaldi active positions
| Companies | Position | Start |
|---|---|---|
| KEROS THERAPEUTICS, INC. | Chief Operating Officer | 2022-01-31 |
NS Pharma, Inc.
 NS Pharma, Inc. Pharmaceuticals: MajorHealth Technology Part of Nippon Shinyaku Co., Ltd., NS Pharma, Inc. operates as a biopharmaceutical company. The company is based in Paramus, NJ. | President | 2019-04-30 |
Former positions of Christopher Rovaldi
| Companies | Position | End |
|---|---|---|
| ACCELERON PHARMA INC. | Chief Operating Officer | 2018-04-30 |
| IDENIX PHARMACEUTICALS INC | Corporate Officer/Principal | 2006-12-31 |
| CUBIST PHARMACEUTICALS INC | Corporate Officer/Principal | 2003-12-31 |
Periodontix, Inc.
 Periodontix, Inc. Miscellaneous Commercial ServicesCommercial Services Part of ACI Global Corp., Periodontix, Inc. is a biopharmaceutical company that specializes in researching and developing next-generation antimicrobial agents for the prevention and treatment of periodontal disease. The company is based in Watertown, MA. Periodontix was acquired by Demegen, Inc. on July 16, 2001 for $8.02 million. | Corporate Officer/Principal | - |
Training of Christopher Rovaldi
| University of New Hampshire | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| KEROS THERAPEUTICS, INC. | Health Technology |
| Private companies | 5 |
|---|---|
Cubist Pharmaceuticals LLC
 Cubist Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Cubist Pharmaceuticals LLC operates as a biopharmaceutical company. It focuses on the research, development and commercialization of pharmaceutical products. The company was founded in 1992 and is headquartered in Lexington, MA. | Health Technology |
Idenix Pharmaceuticals LLC
 Idenix Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Idenix Pharmaceuticals LLC is a biopharmaceutical company, which is engaged in the discovery and development of drugs for the treatment of human viral diseases with operations in the United States and France. Currently, its primary research and development focus is on the treatment of patients with hepatitis C virus, or HCV, using nucleotide polymerase inhibitors and NS5A inhibitors. Idenix Pharmaceuticals was founded by Jean-Pierre Sommadossi and Raymond F. Schinazi in May 1998 and is headquartered in Cambridge, MA. | Health Technology |
Acceleron Pharma, Inc.
 Acceleron Pharma, Inc. BiotechnologyHealth Technology Acceleron Pharma, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its product candidates include Luspatercept, designed to patients with chronic anemia associated within a wide range of blood diseases; ACE-083, designed for the treatment of focal muscle disorders; and Sotatercept, designed to treat pulmonary arterial hypertension. The company was founded by John L. Knopf and Thomas P. Maniatis on June 13, 2003 and is headquartered in Rahway, NJ. | Health Technology |
Periodontix, Inc.
Periodontix, Inc. Miscellaneous Commercial ServicesCommercial Services Part of ACI Global Corp., Periodontix, Inc. is a biopharmaceutical company that specializes in researching and developing next-generation antimicrobial agents for the prevention and treatment of periodontal disease. The company is based in Watertown, MA. Periodontix was acquired by Demegen, Inc. on July 16, 2001 for $8.02 million. | Commercial Services |
NS Pharma, Inc.
NS Pharma, Inc. Pharmaceuticals: MajorHealth Technology Part of Nippon Shinyaku Co., Ltd., NS Pharma, Inc. operates as a biopharmaceutical company. The company is based in Paramus, NJ. | Health Technology |
- Stock Market
- Insiders
- Christopher Rovaldi
